ATLANTA, GA , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that The Lancet, a peer-reviewed medical journal, will publish an article entitled, "Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomized, double-blind, placebo-controlled trial," in this week's May 24, 2008 issue. The article describes the results from AtheroGenics' 6,144-patient ARISE outcome trial of its novel diabetes drug candidate, AGI-1067.

"The ARISE trial has provided us with evidence that succinobucol may be a promising new therapy, based on clinical activity in a number of prespecified diabetes and cardiovascular endpoints," stated Dr. Jean-Claude Tardif, Co-Primary Investigator of the ARISE study, director of the Montreal Heart Institute Research Centre and professor of medicine at the Montreal Heart Institute and the Universit� de Montr�al. "Although ARISE missed its primary endpoint of reducing a composite of cardiovascular endpoints, we believe the study data clearly indicate that succinobucol should be further investigated to confirm its ability to improve glucose control in patients with diabetes and to reduce cardiovascular events in patients with heart disease."

Interested parties will be able to access this week's edition of The Lancet by visiting their website on Saturday, May 24th, 2008 at http://www.thelancet.com/. Once you access the website, click on "This Week's Issue," and then click on "articles."

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). The Company's lead antioxidant and anti-inflammatory drug candidate, AGI-1067, is being studied in a Phase III clinical trial known as ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study), for the treatment of diabetes. In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection. For more information about AtheroGenics, please visit http://www.atherogenics.com.

Disclosure Regarding Forward-Looking Statements

Statements contained in this press release that relate to events or developments that we expect or anticipate will occur in the future are deemed to be forward-looking statements, and can be identified by words such as "believes," "intends," "expects" and similar expressions. AtheroGenics cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. For example, additional information relating to the safety, efficacy or tolerability of AGI-1067, may be discovered upon further analysis of trial data. The U.S. Food and Drug Administration might not allow us to conduct further studies of the efficacy of AGI-1067 for the same or new endpoints, and, to the extent approved, additional clinical trial work may take a significant period of time to complete or require significant additional resources to complete. We cannot ensure that AGI-1067 will ever be approved or be proven safe and effective for use in humans. These and other risks are discussed in AtheroGenics' Securities and Exchange Commission filings, including, but not limited to, the risks discussed in AtheroGenics' Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and are specifically incorporated by reference into this press release. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACTS: AtheroGenics, Inc. Mark P. Colonnese Executive Vice President 678-336-2511 Email Contact Media Inquiries Jayme Maniatis / Dana Conti Schwartz Communications, Inc. 781-684-0770 Email Contact Investor Inquiries Lilian Stern Stern Investor Relations, Inc. 212-362-1200 Email Contact

Grafico Azioni Atherogenics (NASDAQ:AGIX)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Atherogenics
Grafico Azioni Atherogenics (NASDAQ:AGIX)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Atherogenics